Veliparib - Abbvie

Drug Profile

Veliparib - Abbvie

Alternative Names: ABT 888; NSC 737664

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories; University of Alabama at Birmingham
  • Developer Abbott Laboratories; AbbVie; Georgetown University; Narodny onkologicky ustav; National Cancer Institute (USA); Northwestern University; University of Alabama at Birmingham
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Colorectal cancer; Germ cell and embryonal neoplasms; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours
  • Phase I/II Glioma; Head and neck cancer; Small cell lung cancer
  • Phase I Lymphoma
  • No development reported Multiple myeloma; Prostate cancer
  • Discontinued Liver cancer

Most Recent Events

  • 23 Aug 2018 National Cancer Institute re-initiates a phase II trial in Rectal cancer (Neoadjuvant therapy, Late-stage disease, First-line therapy, Combination therapy) in USA (PO) (NCT02921256)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, First-line therapy) in Japan (PO, Capsule)
  • 10 Jul 2018 National Cancer Institute plans a phase II trial for Glioblastoma in USA , (NCT03581292)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top